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A B S T R A C T
Objectives: A major regulatory peptide in iron metabolism, hepcidin, has been shown to predict mortality
in HIV-infected tuberculosis patients. The aim of this study was to evaluate whether plasma hepcidin
levels on admission can be used to predict the treatment outcome of patients with smear-positive
pulmonary tuberculosis (PTB) without HIV co-infection.
Methods: In this prospective observational study, a total of 35 PTB patients with Mycobacterium
tuberculosis-positive sputum smears were enrolled. The relationship between plasma hepcidin levels on
admission and the time period to sputum culture-negative was explored.
Results: Plasma hepcidin levels of PTB patients were significantly higher than those of healthy subjects
(p < 0.001). A positive correlation between hepcidin level on admission and the period until culture-
negative was also observed (r = 0.46, p = 0.006). Furthermore, the hepcidin level showed a negative
correlation with spot numbers in the positive control wells of the T-SPOT.TB assay; thus the effect of the
peptide on interferon-gamma production in T cells was explored. Hepcidin reduced interferon-gamma
gene transcription and interferon-gamma production in a dose-dependent manner in Jurkat cells
stimulated with phytohaemagglutinin, an antigen non-specific stimulation.
Conclusions: These findings indicate that hepcidin alters immunological reactions against M. tuberculosis
infection and has an influence on the outcomes of PTB patients without HIV co-infection.
© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Tuberculosis (TB), a contagious disease, is usually transmitted by
an aerosol of Mycobacterium tuberculosis, such as that caused by
coughing. Although the global incidence of TB is gradually declining,
there were still 9 million cases and 1.5 million deaths in 2013. In
some parts of the world, especially in Africa, the incidence and drug
resistance of TB remain a concern (Zumla et al., 2015).
Iron is an essential factor for both humans and pathogenic
microbes, including M. tuberculosis (Ganz, 2018; Posey and
Gherardini, 2000; Ratledge, 2004). Hepcidin is considered a
major regulatory peptide in iron metabolism. The major role
of this peptide is controlling the expression of ferroportin, a
transmembrane protein responsible for iron transportation from
the inside to the outside of a cell. Iron transportation by ferroportin
is especially important in iron absorption from enterocytes,
macrophages, and hepatocytes (Donovan et al., 2005). Internali-
zation and degradation of ferroportin are promoted by binding to
hepcidin (Delaby et al., 2005; Donovan et al., 2005; Ganz, 2006;
Nemeth et al., 2004; Rivera et al., 2005).
Along with plasma concentrations and body stores of iron,
hepcidin production is regulated by other factors, such as
inflammation and hypoxia. For example, interleukin 6 (IL-6) is
an important upstream mediator of hepcidin induction by
inflammation (Sangkhae and Nemeth, 2017). Hypoxia has been
reported to influence hepcidin expression (Silva et al., 2018;
Sonnweber et al., 2014).
Hepcidin also has potency to modulate immunological reac-
tions. Ferroportin (a target of hepcidin) overexpression on
macrophages has been found to significantly impair intracellular
M. tuberculosis growth during the early stages of infection in vivo
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(Johnson et al., 2010). Hepcidin suppresses lipopolysaccharide-
induced IL-6 and tumour necrosis factor alpha transcription and
production in macrophages (De Domenico et al., 2010). Human
hemochromatosis protein, another iron metabolism peptide, also
has various immunological functions (Reuben et al., 2017).
These findings raise the question of whether iron-related factors
might have some influence on immunological reactions and the
clinical course in M. tuberculosis infection. Hepcidin levels have
already shown predictive ability for the prospective risk of
M. tuberculosis infection (Minchella et al., 2014) and mortality by
active M. tuberculosis infection (Kerkhoff et al., 2016) in individuals
with HIV infection. Furthermore, hepcidin levels are constant over
age in healthy individuals except premenopausal women. On close
investigation, a diurnal variation of hepcidin levels has been
recognized (Schaap et al., 2013); however, the range of fluctuation of
this diurnal variation is difficult to detect by enzyme-linked
immunosorbent assay (ELISA) (Galesloot et al., 2011).
These features of the peptide appear favourable to adapt in
clinical practice. However, reports on the predictive utility of the
peptide in TB patients without HIV co-infection are limited. In a
study only including a small proportion of HIV co-infected
subjects, hepcidin levels of active TB patients at diagnosis were
significantly higher than those of both tuberculin skin test (TST)-
negative and positive contacts without active disease (Minchella
et al., 2015). Another study conducted in Tanzania addressed
household TB contacts and found that those who developed active
disease possessed higher hepcidin levels than those who did not
develop active disease, even in subjects without HIV co-infection
(Hella et al., 2018).
This prospective observational study investigated hepcidin
levels on admission and the time required to achieve sputum
culture-negative status, as a clinical indicator for anti-TB treat-
ment. Hepcidin levels and the time to culture-negative showed a
positive correlation. Due to the negative correlation found between
hepcidin levels and spot numbers in the positive control wells of
enzyme-linked immunospot assays (T-SPOT.TB; Oxford Immuno-
tec, Oxford, UK) observed in the pulmonary TB (PTB) patients in
this study, the influence of the peptide on the immunological
function of T cells was investigated, as the influence of hepcidin on
macrophages has been evaluated previously. In the present study it
was found that hepcidin has the potency to reduce interferon-
gamma gene (IFNG) transcription and interferon-gamma (IFN-g)
production in CD4 + T cells against non-specific stimulations.
Materials and methods
Ethics statement
The study protocol was approved by the Institutional Review
Board of Yokohama City University School of Medicine and was
registered in the University Hospital Medical Information Network
Clinical Trials Registry (UMIN000016454). Informed consent was
obtained appropriately for the study subjects.
Subjects
From February 2015 to February 2016, sputum smear-positive
PTB patients without HIV infection, admitted for isolation and
treatment at Yokohama City University Hospital, were enrolled in
this prospective observational study. All PTB patients were
confirmed to have M. tuberculosis infection with conventional
commercially available nucleic acid amplification tests, using acid-
fast test-positive specimens. HIV infection status was evaluated by
HIV Ag/Ab Combo test (Abbott Laboratories, Abbott Park, IL, USA) at
the time of admission. Subjects with negative sputum culture,
multidrug-resistant M. tuberculosis, those who had already started
anti-TB therapy before hospitalization, those who were younger
than 18 years of age, and those who had been admitted repeatedly
due to TB were excluded.
The patients underwent clinical examinations and investiga-
tions of the levels of iron-related factors at admission for isolation
and initiation of anti-TB chemotherapy. Laboratory tests except
those for hepcidin were conducted in the hospital laboratory using
peripheral blood specimens collected in vacutainer tubes con-
taining clot activator. Serum iron was measured with a colorimetric
method (Nitroso-PSAP method), ferritin by latex agglutination
method, and transferrin and C-reactive protein (CRP) with an
immunoturbidimetric method, using a LABOSPECT 008 analyzer
(Hitachi High-Technologies Co., Tokyo, Japan). Blood samples for
T-SPOT.TB assays were obtained at the time of hospitalization
before treatment initiation using vacutainer tubes containing
heparin. Samples for the T-SPOT.TB were transferred to an outside
laboratory (SRL Inc., Tokyo, Japan) for the assays. Spot numbers of
wells (NIL, ESAT6, CFP10, and mitogen) for each sample were
reported. The results of the assays were interpreted by subtracting
the spot count in the negative control (NIL) from the spot count in
panels A and B; the results were reported as positive >8 spots,
negative <4 spots, borderline 5, 6, or 7 spots, or invalid. All healthy
control subjects enrolled were healthcare workers from the facility
in the hospital and were confirmed not to have had a previous M.
tuberculosis infection by T-SPOT.TB.
Bacteriological examination
Patient sputum samples were collected weekly. Samples were
decontaminated, pelleted by centrifugation, examined for acid-fast
bacilli (AFB) by fluorescence microscopy, and tested for M.
tuberculosis by liquid culture with mycobacterial growth indicator
tubes (Becton Dickinson, Sparks, MD, USA). The period from
hospitalization to the day on which the third weekly consecutive
culture-negative sputum sample was obtained was defined as the
time to sputum culture-negative. The smear grade showing
bacterial load was classified into four classes based on the Japanese
guidelines using Ziehl–Neelsen stain (1000): (), 0 AFB/300
fields; (), 1–2 AFB/300 fields; (+), 1–9 AFB/100 fields; (2+), 10–999
AFB/100 fields; and (3+), 10 AFB/field.
Anti-TB chemotherapy
Treatment regimens used in this study were the standard
regimens recommended by the Japanese Society for Tuberculosis.
Basically, subjects in this study received 2 months of daily oral
isoniazid (5 mg/kg of body weight; maximum 300 mg/day),
rifampicin (10 mg/kg; maximum 600 mg/day), pyrazinamide
(25 mg/kg; maximum 1.5 g/day), and ethambutol (15 mg/kg;
maximum 750 mg/day), followed by 4 months of isoniazid and
rifampicin at the same daily doses. In cases with drug-induced
liver dysfunction, treatment with 2 months of daily oral isoniazid,
rifampicin, and ethambutol, followed by 7 months of isoniazid
and rifampicin at the same daily doses given above was
employed.
Measurement of plasma hepcidin levels
Peripheral blood specimens were collected in vacutainer tubes
containing ethylenediaminetetraacetic acid (EDTA)-Na (Terumo,
Tokyo, Japan). Whole blood samples were centrifuged for 10 min at
200 g (1500 rpm). Then, supernatant plasma samples were
dispensed and preserved at 80 C until measurement. Measure-
ment of plasma hepcidin levels was conducted using an ELISA kit
(Hepcidin 25 Bioactive; DRG Instruments GmbH, Marburg,
Germany) according to the manufacturer’s instructions.
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Cells and media
Jurkat cells (ATCC TIB-152) were cultured in RPMI 1640 (Thermo-
Fisher Scientific, Pittsburgh, PA, USA) with 10% foetal bovine serum
(FBS) at 37 C in 5% CO2. Recombinant hepcidin (Wako, Osaka, Japan)
was employed to evaluate the effect on IFNG transcription and IFN-g
production. According to the manufacturer, the recombinant
hepcidin used in the study contains the active form hepcidin-25
with purity of 98% or more. Hepcidin was dissolved in phosphate-
buffered saline (PBS) and the concentration was adjusted.
Measurement of IFNG transcription levels
Jurkat cells (5 105 cells/well) were cultured in 48-well plates
with or without hepcidin (Wako, Osaka, Japan) for 2 h, then
stimulated with a final concentration of 0.0005% phytohaemag-
glutinin (PHA) for 2 h. To measure IFNG mRNA transcription levels,
total RNA was isolated from Jurkat cells using the RNeasy Mini Kit
(Qiagen,Hilden, Germany). Synthesis of cDNA from100 ng total RNA
was conducted using the iScript cDNA synthesis kit (Bio-Rad,
Hercules, CA, USA). Quantitative real-time PCR was performed on
the StepOne Plus Real-Time PCR systemwith TaqMan Fast Advanced
Master Mix and Gene Expression Assays for IFNG and the
glyceraldehyde-3-phosphate dehydrogenase gene (GAPDH) as a
standard (Applied Biosystems, Waltham, MA, USA). All experiments
were conducted according to the manufacturer’s instructions.
Measurement of IFN-g production levels
Jurkat cells (2.5 105 cells/well) were cultured in 48-well plates
with or without hepcidin (Wako, Osaka, Japan) for 2 h, then
stimulated with a final concentration of 0.001% PHA for 24 h. The
cell culture supernatants of Jurkat cells were measured with
human IFN-g Quantikine enzyme-linked immunosorbent assay
(ELISA) kits (R&D Systems, Minneapolis, MN, USA) as per the
manufacturer’s procedures.
Statistical analysis
The Mann–Whitney U-test was used to compare plasma
hepcidin levels of PTB patients and healthy subjects. To evaluate
correlations between plasma hepcidin levels and other clinical
characteristics, Spearman’s correlation test was used. To evaluate
time-dependent event outcomes, the Kaplan–Meier curve and log-
rank test for trend were applied. The Cox proportional hazards
model was used to assess the impact of laboratory data and time to
culture-negative. The relationship between hepcidin levels and
smear results on admission was evaluated by Mann–Whitney U-
test. Sputum smear on admission was converted to a binary
outcome 0, 0.5, 1, 2 or 3. The paired t-test was used to identify
significant differences between the two groups in quantitative
real-time RT-PCR analysis for IFNG and ELISA for IFN-g. p-Values of
less than 0.05 were considered significant. In the in vitro study, all
experiments were conducted more than three times independent-
ly. Data are expressed as the mean value  standard error of the
mean (SEM). All analyses were conducted using GraphPad Prism
version 7 (GraphPad Software, San Diego, CA, USA) and JMP Pro 12
(SAS Institute Inc., Cary, NC, USA).
Results
Patient and subject characteristics
From February 2015 to February 2016, 35 PTB patients and 15
control subjects were enrolled. Characteristics of the subjects are
shown in Table 1. The mean age of the control group subjects was
significantly lower than that of the PTB group patients. The type (with
or without cavities) and distribution of pulmonary lesions were
evaluated by computed tomography (CT). For subjects with symptom
(s) unlikely to be from respiratory lesions, CT and/or magnetic
resonance imaging examinations were conducted to evaluate
extrapulmonary lesion(s) (Table 2). No strains isolated from PTB
patientsinthisstudyshowedresistancetothefourstandardtreatment
drugs (isoniazid, rifampicin, pyrazinamide, and ethambutol).
Plasma hepcidin levels in PTB patients
Plasma hepcidin levels of PTB patients were significantly higher
than those of healthy subjects (p < 0.001) (Table 1). Serum iron
levels of PTB patients were lower than the lower limit of normal
(Table 2). As hepcidin has a major role in the regulation of serum
iron concentration, it was expected that hepcidin levels would
show a significant correlation with serum iron levels, but they did
not (Figure 1A). There was a negative correlation between hepcidin
levels and serum transferrin levels (Figure 1B). The levels of the
peptide showed a positive correlation with levels of serum ferritin,
a peptide complex related to iron storage (Figure 1C). Since
hepcidin production is regulated by IL-6, the correlation between
hepcidin and CRP, another IL-6-induced protein, was examined and
showed a positive correlation (Figure 1D). To identify any influence
of infection burden on hepcidin levels, AFB smear status, the types
of lung lesions (with or without cavities), and the distribution of
lung lesions (unilateral or bilateral) were evaluated with regard to
hepcidin levels; no significant differences were identified
(Table 3A–C). These results indicate that hepcidin production is
controlled by factors other than iron levels in PTB patients.
Hepcidin levels associated with time to culture-negative
The correlation between hepcidin levels on admission and time
to achieve sputum culture-negative status was examined, and a
positive correlation was found (r = 0.46, p = 0.006) (Figure 2A). CRP
Table 2
Clinical features of pulmonary tuberculosis patients.
TB lesions
Bilateral pulmonary lesions 21 (60.0%)
With cavity lesion(s) 17 (48.6%)
With extrapulmonary lesion(s) 3 (8.6%)
Comorbidities
Immunosuppressive state 3 (8.6%)
Chronic liver disease 1 (2.9%)
Chronic renal disease 3 (8.6%)
Active malignancy 2 (5.7%)
Laboratory data
Haemoglobin (g/dl) 11.5  2.2
Fe (mg/dl) 41.9  31.7
Ferritin (ng/ml) 364.8  427.5
Transferrin (mg/dl) 159.2  55.7
CRP (mg/dl) 5.82  5.5
Sputum smear AFB 2+ 16 (45.7%)a
TB, tuberculosis; CRP, C-reactive protein; AFB, acid-fast bacilli. Laboratory data are
expressed as mean values  standard deviation.
a Number and ratio of patients with more than 10 AFB/100 fields.
Table 1
Characteristics of the study subjects.
PTB patients (n = 35) Controls (n = 15) p-Value
Age (years) 66.2  19.2 30.5  3.9 <0.001
Sex, male 20 (57.1%) 10 (66.7%) 0.54
Hepcidin (ng/ml) 45.1  20 26.4  9.7 <0.001
PTB, pulmonary tuberculosis. Age data and hepcidin levels are expressed as the mean
value  standard deviation. All p-values were derived by Mann–Whitney U-test.
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levels also showed a positive correlation with time to culture-
negative (r = 0.45, p = 0.007) (Figure 2B), consistent with the
correlation between them. Other factors did not exhibit better
correlations than hepcidin levels (Figure 2C–E). As the overall
median value of hepcidin in the PTB group was 48.2 ng/ml, the PTB
patients were categorized into two groups in order to assess the
influence of hepcidin: high hepcidin (50 ng/ml) and low hepcidin
(<50 ng/ml). The time to achieve culture-negative status was
compared between the two groups using the Kaplan–Meier curve
and log-rank test for trend. The high hepcidin group required
significantly longer to achieve negative culture (p = 0.005)
(Figure 3). Next, the burden of infection, in addition to the
distribution of lung lesions (unilateral or bilateral) and smear
grade were compared between the high hepcidin and low hepcidin
groups. There were no statistically significant differences between
them (Table 3). Multivariate analysis was performed on laboratory
data (hepcidin, CRP, and iron), with significant differences found in
the univariate analysis. In the Cox proportional hazards analysis,
serum iron and hepcidin were found to independently affect the
time to culture-negative (Table 4).
Figure 1. Scatter plot of hepcidin levels on admission versus laboratory data. The vertical position of each dot indicates the hepcidin level. The horizontal position of each dot
shows the level of the indicated factor. (A) Serum iron; (B) serum transferrin; (C) serum ferritin; (D) serum CRP. Correlation between two variables was evaluated using
Spearman’s correlation test. r: Spearman’s rank correlation coefficient.
Table 3
Relationship between hepcidin levels and infection burden.
(A) Relationship between hepcidin levels and AFB
Hepcidin 50 ng/ml (n = 17) Hepcidin <50 ng/ml (n = 18) p-Value
AFB (0.5, 1, 2, or 3) 1 (1–2.5) 1 (1–2) 0.61
(B) Plasma hepcidin levels and types of lung lesions (with or without cavities)
With cavity lesion(s) (n = 17) No cavity lesion (n = 18) p-Value
Hepcidin (ng/ml) 48.2  20.9 42.0  19.2 0.26
(C) Plasma hepcidin levels and distribution of lung lesions (unilateral or bilateral)
Bilateral pulmonary lesions (n = 21) Unilateral pulmonary lesion(s) (n = 14) p-Value
Hepcidin (ng/ml) 45.3  21.0 44.6  19.3 0.91
AFB, acid-fast bacilli. The AFB value is expressed as the median value with interquartile range. The p-value was derived by Mann–Whitney U-test.
Hepcidin levels are expressed as the mean value  standard deviation. The p-value was derived by Mann–Whitney U-test.
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Influence of hepcidin on T cell IFN-g production under non-specific
stimulation
During exploration for clinical features associated with
hepcidin levels, a negative correlation was unexpectedly identified
between hepcidin levels and the spot numbers in positive control
wells of the T-SPOT.TB assay (r = 0.38, p = 0.028) (Figure 4A).
Although the cause was not identified, it has been reported that the
spot numbers in the positive control wells of active PTB patients
are lower than those of patients with latent M. tuberculosis
infections (LTBI) (Wang et al., 2016). Hepcidin levels have been
shown to be higher in active PTB patients than in those without
active TB lesions (Minchella et al., 2015), as shown in the present
study. These results led to the hypothesis that hepcidin directly
affects IFN-g production in T cells responding to PHA, a non-
specific stimulation.
To clarify the possible negative effect of hepcidin on IFN-g
production in T cells, IFNG mRNA transcription levels in Jurkat
cells, immortalized T lymphocytes, were quantified. Jurkat cells
were cultured in several concentrations of hepcidin and then
stimulated with PHA. The results showed that hepcidin decreased
IFNG transcription (p = 0.015) and IFN-g production (p = 0.001)
levels in a dose-dependent manner in PHA-stimulated Jurkat cells
(Figure 5A and B, respectively).
Next, the effect of hepcidin on the CD4 + T cell response to
antigen-specific stimulation was investigated in T-SPOT.TB
assays. There was no significant difference in mean spot
numbers or ratio against spots in the positive control well
(Supplementary Material, Table S1); however, a negative
correlation between hepcidin levels and spot numbers was
identified in ESAT6 (r = 0.45, p = 0.007), but not in CFP10
(r = 0.076, p = 0.7) (Figure 4B and C).
Figure 2. Scatter plot of laboratory data on admission versus days to culture-negative. The vertical position of each dot shows the level of the indicated factor. (A) Hepcidin, (B)
serum CRP, (C) serum iron, (D) serum transferrin, (E) serum ferritin. The horizontal position of each dot indicates the days to culture-negative. Correlation between these two
variables was evaluated using Spearman’s correlation test. r: Spearman’s rank correlation coefficient.
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Discussion
This study suggests that the response to anti-TB chemotherapy
in PTB patients varies with hepcidin concentration.
Hepcidin is a peptide hormone secreted mainly by hepatocytes,
but also by a variety of other cells. Hepcidin was initially identified
as a member of the defensin family. As an antimicrobial peptide,
this peptide has been reported to have the ability to cause
structural damage to M. tuberculosis residing in phagosomes of
macrophages, subsequently inhibiting M. tuberculosis growth (Sow
et al., 2007). Along with this direct antimycobacterial activity,
hepcidin plays an important role in iron homeostasis. In short,
hepcidin binds to the cell surface iron transporter ferroportin,
leading to its internalization and degradation (Zhao et al., 2013).
Hepcidin synthesis is not only influenced by iron levels (Ganz and
Nemeth, 2015), and hepcidin secretion is increased in response to
infection or inflammation, leading to hypoferraemia caused by
inflammation (Goodnough et al., 2010; Nicolas et al., 2002).
Iron redistribution caused by increased hepcidin can be
protective against malarial and extracellular bacterial infections
(Arezes et al., 2015; Ganz and Nemeth, 2015). In contrast, as
reported by studies in mouse models, hepcidin-induced iron
sequestration may be beneficial for intracellular microorgan-
isms (Nairz et al., 2009), including M. tuberculosis (Olakanmi
et al., 2007).
With regard to clinical findings, higher hepcidin levels were
found to indicate a significantly greater risk of developing M.
tuberculosis infection in subjects with newly diagnosed HIV
infection (Minchella et al., 2014). High hepcidin concentrations
have also been strongly associated with disseminated disease and a
poor prognosis in patients with HIV-associated TB (Kerkhoff et al.,
2016). However, information about the influence of hepcidin on
the clinical course of M. tuberculosis without HIV co-infection is
limited. Therefore, the present study was performed to explore the
possible effect of hepcidin on the clinical course of M. tuberculosis
without HIV infection.
To assess the effect of hepcidin on the clinical course of
M. tuberculosis infection, the time to culture-negative status in PTB
patients was investigated. In Japan, loss of infectivity is defined as
three consecutive negative sputum cultures; thus, microbiological
examinations of respiratory specimens are regularly conducted.
Moreover, microbiological testing directly reflects the efficacy of
anti-TB chemotherapy. Other elements, for example, hospitaliza-
tion days or the period until hospital death, could be strongly
influenced by comorbidities and medical or social conditions. The
results of this study showed that higher hepcidin concentrations at
treatment initiation were associated with a longer time to culture-
negative status (Figure 2A and 3).
As reported previously (Kerkhoff et al., 2016; Wisaksana et al.,
2013), plasma hepcidin levels were found to be significantly higher
in PTB patients than in healthy control subjects (Table 1). A
significant difference in age between the PTB and healthy groups
was observed; however, plasma hepcidin levels are reportedly not
influenced by age (Galesloot et al., 2011). In general, hepcidin
production is regulated by iron levels. In the present study, levels of
hepcidin and iron did not show a stronger association than
Figure 3. Kaplan–Meier analysis for time to culture-negative. Pulmonary
tuberculosis subjects were categorized into two groups: high hepcidin (50 ng/
ml hepcidin) and low hepcidin (<50 ng/ml). The time taken to achieve culture-
negative status was compared between the two groups using the Kaplan–Meier
curve and log-rank test for trend. p: log-rank test for trend.
Table 4
Cox proportional hazards analysis.
HR (95% CI) p-Value
Hepcidin 0.977 (0.959–0.997) 0.024
CRP 0.992 (0.911–1.075) 0.856
Fe 1.013 (1.002–1.023) 0.023
HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein.
Figure 4. Scatter plot of hepcidin levels on admission versus spot numbers of
positive control, ESAT6, and CFP10 wells in the T-SPOT.TB assays. The vertical
position of each dot indicates the hepcidin level. The horizontal position of each dot
indicates the spot numbers in the T-SPOT.TB assays. (A) Log10 positive control; (B)
ESAT6; (C) CFP10. Correlation between these two variables was evaluated using
Spearman’s correlation test. r: Spearman’s rank correlation coefficient.
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hepcidin levels and other factors, suggesting that hepcidin
production is strongly controlled by factors other than iron status
under the condition of M. tuberculosis infection. Levels of hepcidin
showed a positive relationship with CRP, a biomarker of
inflammation, and ferritin (Figure 2C, D). Ferritin, as an acute
phase protein, is also strongly influenced by inflammation
(Namaste et al., 2017). The effects of inflammation on nutritional
biomarkers, especially iron-related factors, have been assessed by a
collaborative research group called Biomarkers Reflecting Inflam-
mation and Nutrition Determinants of Anemia (BRINDA) (Suchdev
et al., 2016). While this project was not conducted with TB subjects,
reports from the research group can be applied to interpret iron
status and iron-related factors under inflammation caused by TB. It
remains uncertain whether hepcidin has direct effects on ferritin
production or not.
In addition to its influence on macrophages (De Domenico et al.,
2010; Ganz and Nemeth, 2015), hepcidin was found to reduce IFNG
transcription and IFN-g production against non-specific stimula-
tion in T cells (Figure 5A, B). These findings indicate that hepcidin
could directly affect IFN-g production in T cells. IFN-g is essential
in the host defence against mycobacterial infection, including
infection by M. tuberculosis (Flynn et al., 1993; Kampmann et al.,
2005). In HIV-infected individuals, the risk of TB incidence is
increased with declining CD4+ cells count, a major source of IFN-g
(Ellis et al., 2017). Decreased IFN-g production in T cells caused by
hepcidin may impair the protective capability against M. tubercu-
losis, resulting in a prolonged time to culture-negative. This
suppressive effect of hepcidin on IFN-g production in peripheral
blood T cells from PTB patients was only observed under
stimulation with ESAT6 and not with CFP10 (Figure 4).
Several limitations of this study should be addressed. First, this
was a single-centre study in a developed country with moderate TB
incidence. Therefore, the range and effect of hepcidin might differ
in other settings, such as developing countries with a high TB
incidence. In developing countries with high TB incidence,
inadequate nutritional conditions, especially for iron, may have
an influence on the clinical course of PTB. Second, all of the PTB
patients in this study required isolation due to respiratory lesions
with transmission capacity. In patients with less or more severe
conditions, for instance patients with no transmission capacity or
with disseminated and/or central nervous system lesions, the
influence of hepcidin could be different from that observed in the
present study cohort. Third, the evaluation of hepcidin levels was
conducted only at treatment initiation in this study. Fluctuations in
hepcidin levels after starting anti-TB chemotherapy should be
evaluated in a further study. Furthermore, the evaluation of IFN-g
levels in clinical specimens was not conducted in this study. An
effect of hepcidin on IFN-g transcription and production was
observed in ex vivo cells with artificial stimulation. Unfortunately,
the direct relationship between hepcidin and IFN-g levels in
clinical specimens could not be evaluated in this study. Fourth, an
effect of hepcidin on M. tuberculosis-specific antigen stimulation
could be identified only in the ESAT6 wells in this study (Figure 4B
and C). In general, a low frequency of CD4 + T cells specific for an
antigen makes it difficult to conduct direct ex vivo analysis from
clinical subjects, because of sample volume requirements (Uch-
tenhagen et al., 2016). To evaluate an effect on antigen-specific
stimulation, more efficient direct ex vivo analysis or an alternative
method must be considered. While these limitations do not allow
definitive conclusions to be drawn on the direct impact of hepcidin
on the clinical course of PTB patients under treatment, the study
findings may help in the development of an alternative therapeutic
intervention strategy for TB elimination.
As hepcidin pathways are linked with haematological, meta-
bolic, and infectious diseases, therapeutic modulations of hepcidin
pathways have already been under evaluation (Katsarou and
Pantopoulos, 2018). These trials for hepcidin modulations have
mainly been conducted in patients with iron metabolism
disorders; however, studies on immunological functions of
hepcidin could help to expand the clinical utility of hepcidin
modulators in other fields, especially TB infection control.
In conclusion, the plasma hepcidin level on admission for PTB
treatment in the absence of HIV co-infection has the ability to
predict the therapeutic response. The negative influence of the
peptide in reducing IFN-g production from T cells with a non-
specific stimulation partly help to support this finding. It is
necessary to elucidate relevant mechanisms, especially the
response to antigen-specific stimulation and intracellular alter-
ations in T cells by this peptide.
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